A Cincinnati-based life sciences company, Asha Therapeutics, announced the advancement of its development candidate, ASHA-624, as a potential disease modifying therapy for amyotrophic lateral sclerosis (ALS). ASHA-624 is an intra-molecular compound that targets the SARM1 protein, which promotes axonal degeneration and neurodegeneration in ALS. Preclinical models have shown that ASHA-624 can reverse motor impairment and dysfunction, while untreated groups continue to experience decline. This nomination is a significant step for Asha Therapeutics in providing novel therapies for ALS and other neurodegenerative conditions. This announcement follows the previous nomination of ASHA-091 for Alzheimer’s, Parkinson’s, and ALS.
Source link
Intra-molecular compound advanced as potential disease-modifying therapy for ALS
